The role of IL-1β in promoting human CAD was highlighted by the recently concluded CANTOS trial, showing that anti-IL-1β therapy met the primary endpoint, a reduction in a composite of heart attack, stroke and cardiovascular death6. The gene discussed is IL1B; the disease is stroke disorder.